Phosphorylated c-Jun and Fra-1 induce matrix metalloproteinase-1 and thereby regulate invasion activity of 143B osteosarcoma cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 8, 2011, Pages 1543-1553

  Kimura, Ryuichiro ^a   Ishikawa, Chie ^a   Rokkaku, Takayoshi ^a   Janknecht, Ralf ^b   Mori, Naoki ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

C Jun; Fra 1; Invasion; MMP 1; Osteosarcoma; Pulmonary metastasis

Indexed keywords

INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FRA 1;

ARTICLE; BINDING SITE; CANCER INVASION; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION;

BASE SEQUENCE; BINDING SITES; BONE NEOPLASMS; CELL LINE, TUMOR; DNA PRIMERS; GENE EXPRESSION PROFILING; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 1; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; OSTEOSARCOMA; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-FOS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR AP-1;

EID: 79959336476     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.04.008     Document Type: Article

References (41)

1. Whelan J.S. Osteosarcoma. Eur. J. Cancer 1997, 33:1611-1618. discussion 1618-1619.
2. Murphey M.D., Robbin M.R., McRae G.A., Flemming D.J., Temple H.T., Kransdorf M.J. The many faces of osteosarcoma. Radiographics 1997, 17:1205-1231.
3. Stiller C.A., Craft A.W., Corazziari I. Survival of children with bone sarcoma in Europe since 1978: results from the EUROCARE study. Eur. J. Cancer 2001, 37:760-766.
4. Kim S.J., Choi J.A., Lee S.H., Choi J.Y., Hong S.H., Chung H.W., Kang H.S. Imaging findings of extrapulmonary metastases of osteosarcoma. Clin. Imaging 2004, 28:291-300.
5. Kager L., Zoubek A., Potschger U., Kastner U., Flege S., Kempf-Bielack B., Branscheid D., Kotz R., Salzer-Kuntschik M., Winkelmann W., Jundt G., Kabisch H., Reichardt P., Jurgens H., Gadner H., Bielack S.S. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J. Clin. Oncol. 2003, 21:2011-2018.
6. Khanna C., Khan J., Nguyen P., Prehn J., Caylor J., Yeung C., Trepel J., Meltzer P., Helman L. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res. 2001, 61:3750-3759.
7. Lisle J.W., Choi J.Y., Horton J.A., Allen M.J., Damron T.A. Metastatic osteosarcoma gene expression differs in vitro and in vivo. Clin. Orthop. Relat. Res. 2008, 466:2071-2080.
8. Clark J.C., Dass C.R., Choong P.F. A review of clinical and molecular prognostic factors in osteosarcoma. J. Cancer Res. Clin. Oncol. 2008, 134:281-297.
9. Perissinotto E., Cavalloni G., Leone F., Fonsato V., Mitola S., Grignani G., Surrenti N., Sangiolo D., Bussolino F., Piacibello W., Aglietta M. Involvement of chemokine receptor 4/stroma cell-derived factor 1 system during osteosarcoma tumour progression. Clin. Cancer Res. 2005, 11:490-497.
10. Ii M., Yamamoto H., Adachi Y., Maruyama Y., Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp. Biol. Med. (Maywood) 2006, 231:20-27.
11. Liotta L.A., Steeg P.S., Stetler-Stevenson W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64:327-336.
12. Broadhead M.L., Clark J.C.M., Myers D.E., Dass C.R., Choong P.F.M. The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011, 2011:1-12.
13. McAllister R.M., Gardner M.B., Greene A.E., Bradt C., Nichols W.W., Landing B.H. Cultivation in vitro of cells derived from a human osteosarcoma. Cancer 1971, 27:397-402.
14. Rhim J.S., Putman D.L., Arnstein P., Huebner R.J., McAllister R.M. Characterization of human cells transformed in vitro by N-methyl-N′-nitro-N-nitrosoguanidine. Int. J. Cancer 1977, 19:505-510.
15. Hensler P.J., Annab L.A., Barrett J.C., Pereira-Smith O.M. A gene involved in control of human cellular senescence on human chromosome 1q. Mol. Cell. Biol. 1994, 14:2291-2297.
16. Luu H.H., Kang Q., Park J.K., Si W., Luo Q., Jiang W., Yin H., Montag A.G., Simon M.A., Peabody T.D., Haydon R.C., Rinker-Schaeffer C.W., He T.C. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin. Exp. Metastasis 2005, 22:319-329.
17. 2-terminal kinase pathway is involved in constitutive matrix metalloproteinase-1 expression in a hepatocellular carcinoma-derived cell line. Int. J. Cancer 2004, 109:867-874.
18. Ueda M., Shimada T., Goto Y., Tei K., Nakai S., Hisa Y., Kannagi R. Expression of CC-chemokine receptor 7 (CCR7) and CXC-chemokine receptor 4 (CXCR4) in head and neck squamous cell carcinoma. Auris Nasus Larynx 2010, 37:488-495.
19. + T cells. J. Immunol. 2008, 180:931-939.
20. Bosc D.G., Goueli B.S., Janknecht R. HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1. Oncogene 2001, 20:6215-6224.
21. Fuchs B., Inwards C.Y., Janknecht R. Upregulation of the matrix metalloproteinase-1 gene by the Ewing's sarcoma associated EWS-ER81 and EWS-Fli-1 oncoproteins, c-Jun and p300. FEBS Lett. 2003, 553:104-108.
22. Mori N., Prager D. Transactivation of the interleukin-1α promoter by human T-cell leukemia virus type I and type II Tax proteins. Blood 1996, 87:3410-3417.
23. Gutman A., Wasylyk B. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. EMBO J. 1990, 9:2241-2246.
24. Jawad M.U., Garamszegi N., Garamszegi S.P., Correa-Medina M., Diez J.A., Wen R., Scully S.P. Matrix metalloproteinase 1: role in sarcoma biology. PLoS One 2010, 5:e14250.
25. Gueders M.M., Foidart J.M., Noel A., Cataldo D.D. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Eur. J. Pharmacol. 2006, 533:133-144.
26. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
27. Foukas A.F., Deshmukh N.S., Grimer R.J., Mangham D.C., Mangos E.G., Taylor S. Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells. J. Bone Joint Surg. Br. 2002, 84:706-711.
28. Kido A., Tsutsumi M., Iki K., Takahama M., Tsujiuchi T., Morishita T., Tamai S., Konishi Y. Overexpression of matrix metalloproteinase (MMP)-9 correlates with metastatic potency of spontaneous and 4-hydroxyaminoquinoline 1-oxide (4-HAQO)-induced transplantable osteosarcomas in rats. Cancer Lett. 1999, 137:209-216.
29. Westermarck J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999, 13:781-792.
30. Fanjul-Fernandez M., Folgueras A.R., Cabrera S., Lopez-Otin C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim. Biophys. Acta 2010, 1803:3-19.
31. Armstrong D.A., Phelps L.N., Vincenti M.P. CCAAT enhancer binding proteinβ regulates matrix metalloproteinase-1 expression in interleukin-1β-stimulated A549 lung carcinoma cells. Mol. Cancer Res. 2009, 7:1517-1524.
32. Tower G.B., Coon C.I., Belguise K., Chalbos D., Brinckerhoff C.E. Fra-1 targets the AP-1 site/2G single nucleotide polymorphism (ETS site) in the MMP-1 promoter. Eur. J. Biochem. 2003, 270:4216-4225.
33. Keld R., Guo B., Downey P., Gulmann C., Ang Y.S., Sharrocks A.D. The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma. Mol. Cancer 2010, 9:313.
34. Adiseshaiah P., Papaiahgari S.R., Vuong H., Kalvakolanu D.V., Reddy S.P. Multiple cis-elements mediate the transcriptional activation of human fra-1 by 12-O-tetradecanoylphorbol-13-acetate in bronchial epithelial cells. J. Biol. Chem. 2003, 278:47423-47433.
35. Adiseshaiah P., Peddakama S., Zhang Q., Kalvakolanu D.V., Reddy S.P. Mitogen regulated induction of FRA-1 proto-oncogene is controlled by the transcription factors binding to both serum and TPA response elements. Oncogene 2005, 24:4193-4205.
36. Adiseshaiah P., Kalvakolanu D.V., Reddy S.P. A JNK-independent signaling pathway regulates TNFα-stimulated, c-Jun-driven FRA-1 protooncogene transcription in pulmonary epithelial cells. J. Immunol. 2006, 177:7193-7202.
37. Adiseshaiah P., Li J., Vaz M., Kalvakolanu D.V., Reddy S.P. ERK signaling regulates tumor promoter induced c-Jun recruitment at the Fra-1 promoter. Biochem. Biophys. Res. Commun. 2008, 371:304-308.
38. Talotta F., Mega T., Bossis G., Casalino L., Basbous J., Jariel-Encontre I., Piechaczyk M., Verde P. Heterodimerization with Fra-1 cooperates with the ERK pathway to stabilize c-Jun in response to the RAS oncoprotein. Oncogene 2010, 29:4732-4740.
39. O'Hagan R.C., Tozer R.G., Symons M., McCormick F., Hassell J.A. The activity of the Ets transcription factor PEA3 is regulated by two distinct MAPK cascades. Oncogene 1996, 13:1323-1333.
40. Sun X., Wei L., Chen Q., Terek R.M. CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression. Mol. Cancer 2010, 9:17.
41. Huang C.Y., Lee C.Y., Chen M.Y., Yang W.H., Chen Y.H., Chang C.H., Hsu H.C., Fong Y.C., Tang C.H. Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-κB-dependent pathways. J. Cell. Physiol. 2009, 221:204-212.